Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: Regeneron's REGEN-COV Authorized For Prevention

Executive Summary

Regeneron's antibody cocktail gets emergency authorization for post-exposure prophylaxis from the US FDA. Daewoong's camostat shows efficacy in older patients in South Korean trial. 

You may also be interested in...



Antibody COVID-19 Therapies Back in China Spotlight Amid Infection Surge

Chinese developers forge ahead with research into antibody therapies for COVID-19 as coronavirus variants gain a toe-hold in the country.

Regeneron Follows REGEN-COV Revenue Success With Impressive PD-1 Data

Regeneron reported $2.76bn in revenues from the sale of its COVID-19 antibody cocktail, and that Libtayo in combo with chemotherapy was effective in NSCLC.

Pandemic Still Weighs On Gilead’s HIV Business, But Signs Of Recovery

HIV PrEP and treatments saw increases in sales, though the US treatment market’s recovery was slower than expected and may need “several” quarters to return to pre-pandemic levels.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144788

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel